Abstract-Quantitative evaluation of antimuscarinic effects of antihistamines (H1 and H2-receptor antagonists) was carried out using a receptor-binding assay. The inhibition constants (K; values) of twenty seven H1-receptor antagonists, one related antidepressant and three H2-receptor antagonists at Hi-receptors and muscarinic receptors in the bovine cerebral cortex were determined. All the H2 receptor antagonists examined showed very low affinity for the muscarinic receptors. On the other hand, some Hl-receptor antagonists (mequitazine, cyproheptazine, clemastine, diphenylpyraline, promethazine, homochlorcyclizine and alimemazine) had high affinity for the muscarinic receptors (K;=5.0-38 nM). Another group of H, -receptor antagonists (mepyramine, terfenadine, metapyrilen, azelastine, hydroxyzine and meclizine) had low affinity for the muscarinic receptors (K;=3,600 30,000 nM). Thus, a broad range of antimuscarinic potencies among the anti histamines was demonstrated. These results should provide helpful information with regard to the clinical and experimental use of antihistamines.
Histamine has been shown to stimulate two different types of receptors which are referred to as H1 and H2-receptors. Hj receptor mediates histamine-induced con traction of smooth muscles of the small intestine and bronchi. H2-receptor mediates the action of histamine in stimulating gastric acid secretion.
The receptors are defined pharmacologically from the antagonists which selectively block the response of these tissues to histamine stimulation (1, 2) .
Some of the classical H,-receptor an tagonists such as diphenhydramine (3) and antazoline (4) were reported to display substantial atropine-like activity which was assessed by a bioassay system. In the follow ing years, numerous antihistamines of much greater potency and specificity either at H1 or H2-receptors were synthesized. While some of these drugs are thought to possess antimuscarinic activities which may cause certain adverse effects in clinical use, quanti tative evaluation of the antimuscarinic effects has not been reported. Recently, receptor binding studies have provided a new method for quantitative evaluation of the affinities of some drugs for various receptors (5) . In this study, we determined the affinities of a large series of antihistamines for H1 and muscari nic receptors of bovine cerebral cortex using a receptor-binding assay and showed that there is a broad range of antimuscarinic potencies among the antihistamines.
Materials and Methods
Membrane preparations: Bovine brains were obtained from a local slaughterhouse, and stored at -80°C until use. Membrane preparations were prepared as described previously (6) . Briefly, the cerebral cortex was homogenized in 20 volumes of ice-cold 50 mM Tris-HCI (pH 7.4) with a Kinematika Polytron PT-10 (setting 7, 20 sec). The homogenates were centrifuged three times for 10 min at 50,000xg at 4°C with resus pension of the intermediate pellet from each centrifugation in the ice-cold Tris buffer. The final pellets were used immediately or stored at -80°C until assayed.
Radioligand-binding assay: 3 H -mepyra mine and 3H-quinuclidinyl benzilate (QNB) binding assays were performed as described previously (7, 8) . Briefly, the membrane preparations were added to siliconized glass test tubes containing 3H-mepyramine or 3H QNB and various drugs in the Tris buffer, with a final assay volume of 0.6 ml. The assay tubes were incubated for 30 min at 25'C for 3H-mepyramine binding and for 60 min at 25°C for 3H-QNB binding. The incubation was terminated by rapid filtration over poly etylenimine-treated glass fiber filters (9) under vacuum. The filters were then rinsed rapidly with 20 ml of ice-cold Tris buffer. Radioactivity trapped on the filters was counted by liquid scintillation spectroscopy. Nonspecific bindings were determined in the presence of 2 ,uM triprolidine for 3H mepyramine binding and 1 ,uM atropine for 3H-QNB binding . Protein was assayed by the method of Lowry et al. (10) .
Materials: 3H-mepyramine (24.1 Ci/mmol) and 3H-QNB (30.1 Ci/mmol) were obtained from New England Nuclear. Other reagents were purchased from Sigma. Examined com pounds were as follows: mepyramine, me tapyrilen, tripelennamine, dimenhydrinate and antazoline (Sigma); triprolidine and diphen hydramine (Tanabe Pharmaceutical); pro methazine (Shionogi Pharmaceutical); d chlorphenilamine (Shering); doxepin, hydro xyzine and meclizine (Taito-Pfizer); clemas tine and ketotifen (Sandoz); homochlorcy clizine, diphenylpyraline and azelastine (Eisai); mequitazine and ranitizine (Shin nippon Jistugyo); cyproheptazine (Merck Sharp & Dohme); alimemazine (Dai-ichi Pharmaceutical); pyrathiazine (Upjohn); carbinoxamine (Taisho Pharmaceutical); dimethindene (Ciba-Geigy Japan); di pheterol (Toyama Chemical); isothipendyl (Sumitomo Chemical); mebhydroline (Bayer); astemizole (Janssen Pharmaceutical); ter fenadine (Dow Chemical); cimetidine (SK&F Fujisawa); famotidine (Yamanouchi Phar maceutical).
Results 3H-mepyramine binding: Specific 3H mepyramine binding to the membrane pre parations from bovine cerebral cortex was saturable (Fig. 1A) 1A) . These values are in good agreement with data in the literature (11, 12) . As shown in Fig. 2A , the affinities of various H1-receptor antagonists and other drugs for the H1 receptor in the bovine cerebral cortex were determined according to the inhibition of 3H mepyramine binding. The inhibition constants (Ki) were calculated from the equation Ki=1C50/(1 +C/Kd), where IC50=concen tration causing 50% inhibition of specific binding which was obtained from the dis placement experiments, C=3H-ligand con centration used in the displacement experi ment, and Kd= dissociation constant from the Scatchard analysis of the equilibrium experi ments. Calculated Ki values of Hl-receptor antagonists for 3H-mepyramine binding were in the range of 0.24 nM (mepyramine) to 160 nM (antazoline, dipheterol) (Table  1) . Doxepin, an antidepressant, exhibited the most potent H, -receptor antagonism, and all the three H2-receptor antagonists examined showed very low affinities for the H1-receptor ( Fig. 2A and (Fig. 1 B) . These values are in agreement with data in the literature (13, 14) . The Scatchard plot of specific 3H-QNB binding was linear, thereby indicating a single class of high affinity binding sites in the bovine cerebral cortex (Fig. 1B) . As shown in Fig. 2B and Table 1 Doxepin also showed high affinity for the muscarinic receptor, and three H2-antagonists had little cross-reactivity (Table 1) . Hill coefficients for all anti histamines studied were essentially equal to unity (Table 1) , suggesting the antagonistic nature of these compounds for muscarinic receptors (15) .
The ratio of the K; value with 3H mepyramine binding to that with 3H-QNB binding for each drug was calculated in order to quantitatively evaluate the selectivity (Table 1) . Except for several drugs (mepyra mine, metapyrilen, ketotifen, dimethindene, azelastine and hydroxyzine, K; value ratio:::-590-130,000), most H1-receptor antagonists seemed to have substantial interaction with the muscarinic receptors. That is, thirteen compounds out of twenty-seven H1 antagonists had a ratio of less than 100, indicating considerably low selectivity. For example, mequitazine showed almost equal affinities for the H1 and the muscarinic receptors (Ki value ratio=1.1).
Discussion
This paper presents the data of the binding The inhibition of specific binding of 3H-mepyramine (1 nM) and 3H-QNB (1 nM) binding was determined with seven to ten concentrations of competing drugs assayed in triplicate as shown in Fig. 2 . The mean inhibitory concentration (IC50) values were determined from the log-probit analysis, and K; values were calculated from the equation described in "Results". The Hill coefficient (nH) was calculated as described by Bennett and Yamamura (15) and piperazines (meclizine and others). Since scopolamine was reported to be a potent drug for the prophylaxis and treatment of motion sickness (16) , the anti motion sickness activity of some of the H 1 receptor antagonists seems to be related to their antimuscarinic ability. As the histamine H1-receptor blockade is suggested to be associated with the sedative activity (17), use of a drug which has both antimuscarinic and antihistaminic effects may be more effective in the treatment of motion sickness. The ranking of these drugs (Table 1) as anti muscarinic agents also can be used clinically to predict the likelihood that these drugs will cause certain adverse effects in patients such as dry mouth, blurred vision, urinary retention and constipation.
Thus, these results will provide helpful information with regard to the clinical and experimental use of antihistamines.
